C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
AYRWF Equity

Ayr Wellness

OTCMKTS · AYRWF

$0.00
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 2/5
46/100 composite
Fundamentals50
Regulatory58
Market40
Editorial30
Composite · trailing 12 months

Ayr Wellness earns a Neutral rating with a 46.5 composite score and conviction of two out of five. Regulatory is the strongest pillar at 58, supported by an 80 jurisdiction-posture subscore and an 80 enforcement subscore. Fundamentals contribute a middling 50, reflecting resilient gross profitability and positive EBITDA against revenue contraction, operating losses, and a deeply negative bottom line. Market contributes 40 because institutional pricing feeds provide no current quote, limiting confirmation from trading performance. Editorial ranks weakest at 30, with no newsroom or brief activity recorded in CIN newsroom coverage. The resulting pillar mix supports balance rather than directional conviction, while the stretched financial condition limits the significance of positive EBITDA.

Licensed fundamentals data show year-over-year revenue declined roughly 9%, while gross margin held near 35%. Operating margin remained negative at approximately 18.5%, and net income registered a loss of about $310.4 million despite EBITDA of roughly $20.3 million. That combination explains the 50 fundamentals score: gross margin and operating-margin subscores of 58.4 and 62.7 provide support, while the 40.9 revenue-growth subscore and zero market-cap-tier contribution constrain the pillar. Positive EBITDA does not offset the bottom-line loss or stretched condition. Primary regulatory filings show no recorded filing date, producing a cadence subscore of 25. No regulatory events appeared across either the 90-day or 180-day windows, and no enforcement hits were recorded, underpinning the stronger jurisdiction and enforcement components without demonstrating active filing momentum.

The clearest forward catalyst sits within regulatory, the highest-rated pillar. A renewed cadence of timely primary regulatory filings would directly address the pillar’s weakest component and provide fresher evidence on operating performance, financial condition, and corporate execution. Stable jurisdiction posture and the absence of enforcement hits already establish the rating’s strongest foundation; improved disclosure frequency would convert that foundation into a more actionable signal and could strengthen conviction within the Neutral band. The single most important signal to watch is the appearance of a new primary regulatory filing that restores filing cadence.

Scored: 2026-09-22Valid through: 2026-11-06Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Headquarters
199 BAY STREET, SUITE 5300, TORONTO, M5L 1B9
Phone
949-574-3860
SEC CIK
1847462
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$1.5M
Enterprise value
$598.2M
Price to book
0.00
Price to sales
0.00
EV / EBITDA
8.71
Revenue (TTM)
$452.9M
Gross profit (TTM)
$158.8M
EBITDA
$20.3M
Operating margin
-18.4%
Profit margin
-68.5%
Rev growth YoY
-9.1%
Return on equity
-68.0%
Return on assets
-2.6%
EPS (TTM)
$-2.65
Wall St. target price
$1.00
Shares outstanding
108.8M
Insider ownership
9.8%
Institutional ownership
0.7%
Beta
1.01
Full-time employees
2,500
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEDAR+
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Ayr Wellness (AYRWF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Ayr Wellness (AYRWF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Bullish and bearish analyst opinions for Ayr Wellness (AYRWF)

Bullish view. Ayr Wellness operates verticals in Florida, Massachusetts, Pennsylvania, Ohio, and New Jersey and has been a wholesale share gainer in Massachusetts and Ohio; bulls model Florida adult-use as a step-change catalyst if the referendum passes, and Ohio as a leverageable adult-use market that scaled quickly.

Bearish view. Bearish views cite Ayr's balance-sheet leverage, near-term note maturities that require refinancing at higher rates, and the general MSO peer-group multiple compression that has affected leveraged names disproportionately.

Live ratings, price targets, and consensus figures for Ayr Wellness appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for AYRWF are maintained by Cannabis Investor News and refreshed throughout the trading day.